The U.S. Food and Drug Administration (FDA) failed to meet its deadline to provide a Congressionally mandated report on how it plans to regulate CBD. Congress instructed the FDA in last year’s spending bill to adopt an enforcement discretion policy within 120 days and provide an update of its progress after 60 days. The agency’s first report was due on Feb. 20, 2020.
“Unfortunately, this is more of the same from FDA. Each day that goes by elevates the risk of a public health crisis,” said Daniel Fabricant, PhD, president and CEO of the Natural Products Association (NPA).
NPA supports legislation passed by the U.S. House of Representatives that provides resources so the FDA can perform a Health Hazard Evaluation (HHE) and set a safe level of CBD for consumers to use each day. The process would follow the same precedent as red yeast rice, which allows a natural product to contain a level of a drug ingredient that the FDA has determined to be safe. With the exception of Epidiolex, all CBD products in the U.S. are considered illegal by the federal government.
For more information, visit www.npanational.org.
